Cornerstone Planning Group’s Landos Biopharma, Inc. Common Stock LABP Stock Holding History

Cornerstone Planning Group’s Portfolio LABP Stock Details LABP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-12	Closed	-$267	–	1362
2024 Q1	$267	Hold	12	–	–	﹤0.01%	998
2023 Q4	$44	Buy	+12	New	+$47	﹤0.01%	925

Cornerstone Planning Group's LABP Position: Q2 2024 in Review

Cornerstone Planning Group sold out of Landos Biopharma, Inc. Common Stock (LABP) in Q2 2024, closing a stake of 12 shares — an estimated $267 sold.

Cornerstone Planning Group first reported a position in LABP in Q4 2023 and held it in 2 quarters. The position peaked at $267 in Q1 2024. 0 funds tracked by Wall St. Rank hold LABP as of Q2 2024.

Cornerstone Planning Group reported no remaining Landos Biopharma, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Cornerstone Planning Group sold 12 Landos Biopharma, Inc. Common Stock shares in Q2 2024, an estimated $267.
Cornerstone Planning Group first reported a position in Landos Biopharma, Inc. Common Stock in Q4 2023 and held it in 2 quarters.
Cornerstone Planning Group's Landos Biopharma, Inc. Common Stock position peaked at $267 in Q1 2024.
0 funds tracked by Wall St. Rank held Landos Biopharma, Inc. Common Stock as of Q2 2024.

Based on Cornerstone Planning Group's 13F filing for Q2 2024, filed 13 Aug 2024.